Literature DB >> 28539691

Goals Set by Patients Using the ICF Model before Receiving Botulinum Injections and Their Relation to Spasticity Distribution.

Kevin Choi1, Jaclyn Peters1, Andrew Tri1, Elizabeth Chapman1, Ayako Sasaki2, Farooq Ismail2,3, Chris Boulias2,3, Shannon Reid1,2, Chetan P Phadke1,2,4.   

Abstract

Purpose: Goal Attainment Scaling (GAS) is used to assess functional gains in response to treatment. Specific characteristics of the functional goals set by individuals receiving botulinum toxin type A (BoNTA) injections for spasticity management are unknown. The primary objectives of this study were to describe the characteristics of the goals set by patients before receiving BoNTA injections using the International Classification of Functioning, Disability and Health (ICF) and to determine whether the pattern of spasticity distribution affected the goals set.
Methods: A cross-sectional retrospective chart review was carried out in an outpatient spasticity-management clinic in Toronto. A total of 176 patients with a variety of neurological lesions attended the clinic to receive BoNTA injections and completed GAS from December 2012 to December 2013. The main outcome measures were the characteristics of the goals set by the participants on the basis of ICF categories (body functions and structures, activity and participation) and the spasticity distribution using Modified Ashworth Scale scores.
Results: Of the patients, 73% set activity and participation goals, and 27% set body functions and structures goals (p<0.05). In the activity and participation category, 30% of patients set moving and walking goals, 28% set self-care and dressing goals, and 12% set changing and maintaining body position goals. In the body functions and structures category, 18% set neuromuscular and movement-related goals, and 8% set pain goals. The ICF goal categories were not related to the patterns of spasticity (upper limb vs. lower limb or unilateral vs. bilateral spasticity) or type of upper motor neuron (UMN) lesion (p>0.05).
Conclusion: Our results show that patients receiving BoNTA treatment set a higher percentage of activity and participation goals than body functions and structures goals. Goal classification was not affected by type of spasticity distribution or type of UMN disorder.

Entities:  

Keywords:  activities of daily living; botulinum toxin; goals; muscle spasticity; patient participation

Year:  2017        PMID: 28539691      PMCID: PMC5435400          DOI: 10.3138/ptc.2016-25

Source DB:  PubMed          Journal:  Physiother Can        ISSN: 0300-0508            Impact factor:   1.037


  21 in total

1.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

Review 2.  Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb.

Authors:  Lynne Turner-Stokes; Stephen Ashford
Journal:  Disabil Rehabil       Date:  2007-12-15       Impact factor: 3.033

3.  Goal attainment scaling (GAS) in rehabilitation: a practical guide.

Authors:  Lynne Turner-Stokes
Journal:  Clin Rehabil       Date:  2009-01-29       Impact factor: 3.477

4.  Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity.

Authors:  Quan V Doan; Allison Brashear; Patrick J Gillard; Sepideh F Varon; Amanda M Vandenburgh; Catherine C Turkel; Elie P Elovic
Journal:  PM R       Date:  2011-12-24       Impact factor: 2.298

Review 5.  Goal setting as an outcome measure: A systematic review.

Authors:  Jane Hurn; Ian Kneebone; Mark Cropley
Journal:  Clin Rehabil       Date:  2006-09       Impact factor: 3.477

Review 6.  Spasticity treatment with botulinum toxins.

Authors:  A B Ward
Journal:  J Neural Transm (Vienna)       Date:  2008-04-04       Impact factor: 3.575

Review 7.  The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy.

Authors:  Peter Rosenbaum; Debra Stewart
Journal:  Semin Pediatr Neurol       Date:  2004-03       Impact factor: 1.636

Review 8.  Spasticity: a review.

Authors:  R R Young
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

9.  Goal attainment following upper-limb botulinum toxin-A injections: are we facilitating achievement of client-centred goals?

Authors:  Melissa T Nott; Hannah L H Barden; Ian J Baguley
Journal:  J Rehabil Med       Date:  2014-10       Impact factor: 2.912

10.  European consensus table on the use of botulinum toxin type A in adult spasticity.

Authors:  Jörg Wissel; Anthony B Ward; Per Erztgaard; Djamel Bensmail; Martin J Hecht; Thierry M Lejeune; Peter Schnider; Maria C Altavista; Stefano Cavazza; Thierry Deltombe; Esther Duarte; Alexander C H Geurts; Jean-Michel Gracies; Naseer H J Haboubi; Francisco J Juan; Helge Kasch; Christian Kätterer; Yeşim Kirazli; Paolo Manganotti; Yeşim Parman; Tatjana Paternostro-Sluga; Konstantina Petropoulou; Robert Prempeh; Marc Rousseaux; Jaroslaw Slawek; Niko Tieranta
Journal:  J Rehabil Med       Date:  2009-01       Impact factor: 2.912

View more
  1 in total

1.  Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study.

Authors:  Atul T Patel; Theodore Wein; Laxman B Bahroo; Ophélie Wilczynski; Carl D Rios; Manuel Murie-Fernández
Journal:  JMIR Public Health Surveill       Date:  2020-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.